15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Bicycle Therapeutics Ltd, 3 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $7.00 to $36.00 (about 5.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $14.50 sits 262% above the current $4.01. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.41 next quarter toward $-2.22 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy350%
Hold350%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Bicycle Therapeutics Ltd.
As of Sep, 3 of 6 firms rate BCYC a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BCYC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.59 – $0.28 · 8 analysts · +41% YoY
Next period, 8 analysts expect Bicycle Therapeutics Ltd to earn $-0.41 a share (range $-0.59 – $0.28), versus $-0.29 a year earlier. Full-year consensus is $-2.45, growing to $-2.22 the year after.
REVENUE · NEXT QUARTER
$1.6M
Range $200.0K – $6.0M · 8 analysts · -97% YoY
Revenue is expected to reach $1.6M (range $200.0K – $6.0M), -96.6% year-over-year. Full-year consensus is $17.5M, rising to $6.7M next year.
Top analysts covering Bicycle Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCYC.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Hold
$12.00+199.6% to target
Overall win rate
64%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #33
Hold
$5.00+24.8% to target
Overall win rate
48%
+ Follow
#3
Ami Fadia
Needham · Rank #67
Buy
$14.00+249.6% to target
Overall win rate
47%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #213
Buy
$32.00+699.0% to target
Overall win rate
34%
+ Follow
#5
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$33.00+724.0% to target
Overall win rate
38%
+ Follow
BCYC stock forecast FAQ
What is BCYC's average 12-month price target?+
The 6 analysts with a live target average $14.50 for Bicycle Therapeutics Ltd over the next 12 months, ranging from a $36.00 high to a $7.00 low.
Is BCYC stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 3 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BCYC?+
The Street-high target is $36.00 (Oppenheimer), and the Street-low is $7.00 (RBC Capital). The average of all 6 active targets is $14.50.
How many Wall Street analysts cover BCYC?+
6 analysts have an active rating on Bicycle Therapeutics Ltd, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering BCYC?+
Among analysts who currently cover BCYC, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #3). Their current call is Hold with a $12.00 target.
What is Bicycle Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.59 – $0.28) across 8 analysts. Full-year EPS is projected at $-2.45, rising to $-2.22 the following year.
How much revenue is Bicycle Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $1.6M (range $200.0K – $6.0M). Full-year revenue is projected at $17.5M, growing to $6.7M next year.
Have analysts been upgrading or downgrading BCYC lately?+
As of Sep, 3 of 6 firms rate BCYC a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCYC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
